Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes

Diabetes Clinical Trial

Official title:

Effect of Androgel on Total and Regional Adipose Tissue and Lean Body Mass in Type 2 Diabetic Patients With Hypogonadism

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00440440
• Other study ID #: GR-940
• Status: Withdrawn
• Phase: Phase 4
• First received: February 23, 2007
• Last updated: August 6, 2015
• Start date: August 2009
• Est. completion date: July 2012

Study information

• Verified date: August 2015
• Source: Diabetes Center of the Southwest
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to find out the effect of replacing testosterone in the form of a gel (Androgel®) on the amount of fat mass in males with low testosterone and diabetes.

Description:

Hypogonadism is associated with increase in fat mass, decrease in muscle mass, accelerated bone loss, decreased libido and effects on mood. Androgen replacement in this context is clearly beneficial, and numerous studies have demonstrated improvements in bone and muscle mass, reductions in body fat and improvement in insulin sensitivity, libido and mood following treatment. Testosterone replacement leads to a dose-dependent decrease in adipose tissue and increase in muscle mass and strength. The principal focus of the proposed research is to evaluate the effect of androgel on lean body mass and regional adipose tissue mass (including hepatic and visceral fat) in type 2 diabetic patients with hypogonadism, a population that is likely to benefit from a reduction in adipose tissue and an increase in muscle mass.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2012
• Est. primary completion date: November 2011
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

• Males with age 35-75 years inclusive.

• Evidence of hypogonadism: Hypogonadism will be defined as low total testosterone (<300 ng/dL) and low calculated free testosterone (below 6.5ng/dL; calculated using testosterone and SHBG). Testosterone levels will be measured between 8 and 10 am. Subjects who have normal total but low free testosterone levels (or vice versa) will be asked to come again after one week to have their testosterone levels re-measured. They will be included in the study in their free and total testosterone levels are low on re-measurement.

• Type 2 diabetes

• Hemoglobin A1c <8.0 %

• Subjects on medications for diabetes will be allowed as long as they are on stable doses of these compounds for at least 6 weeks. The dose of thiazolidinediones will have to be stable for 3 months prior to the study. The dosage of diabetic medications will not be changed during the study.

Exclusion Criteria:

• Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks

• Hepatic disease (transaminase > 3 times normal)

• Renal impairment (serum creatinine > 1.5)

• Chronic steroid therapy

• Use of testosterone or other androgens (such as DHEA) in the last 3 months

• Panhypopituitarism

• HIV or hepatitis C

• Subjects will be excluded from the study for history of prostate or breast cancer, gonadal endocrine disorders

• Current or recent history of major psychiatric illness, significant uncontrolled systemic illness

• Sleep apnea

• History of alcoholism or substance abuse within the past year

• History of taking other drugs that might interfere with the results of the study (ie, Lupron, finasteride, spironolactone, cimetidine, antiandrogens, estrogens, p450 enzyme inducers, barbiturates)

• Abnormal prostate evidenced by prostatic symptoms, prostatic masses or induration on rectal examination, elevated levels of prostate specific antigen (>4 ng/mL; subjects with PSA levels between 2.5-4 ng/mL will be permitted if prostate biopsy is negative) or positive biopsy, a urine flow rate of less than 12 mL/s, or an International Prostate Symptom Score greater than 19

• Hematocrit greater than 50%

• Body weight >300 lbs (this is the maximum weight that can be accommodated on DEXA or MRI machines.

• The subject has systolic blood pressure >170mmHg or diastolic blood pressure >100 mmHg while on or off anti-hypertensive treatment.

• Generalized skin disease that could affect the absorption of testosterone gel (ie, psoriasis);

• Morning prolactin level greater than 40 mg/mL

• Subjects with serum fasting triglyceride concentration > 500 mg/dL at screening or with history of hypertriglyceridemia-induced pancreatitis.

• Participation in any other concurrent clinical trial

• Any other life-threatening, non-cardiac disease

• Use of an investigational agent or therapeutic regimen within 30 days or 5 half-lives (which ever is longer) preceding the first dose of study medication.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes
• Hypogonadism

Intervention

Drug:
• Testosterone gel
Testosterone gel to be applied daily, starting does 5g.
• placebo
placebo gel apply daily

Locations

Country	Name	City	State
United States	Diabetes Center of the Southwest	Midland	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Diabetes Center of the Southwest	Solvay Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean absolute change in visceral adipose tissue mass in type 2 diabetic subjects with hypogonadism after 6 months of androgel therapy.		6 months	No
Secondary	Study the effect in type 2 diabetic subjects with hypogonadism after 6 months of androgel therapy on:		6 months	No
Secondary	Mean absolute change in hepatic fat measured by NMR spectroscopy.		6 months	No
Secondary	Mean absolute change in total and regional adipose tissue mass measured by DEXA		6 months	No
Secondary	Mean absolute change in total and regional lean body mass measured by DEXA.		6 months	No
Secondary	Mean absolute change in total body and regional (arm, leg, ribs) BMC and BMD		6 months	No
Secondary	Mean absolute change in hip BMC and BMD (mean of two hips)		6 months	No
Secondary	Mean absolute change in spine BMC and lumbar spine (L1-L4) BMD		6 months	No